Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$33.48M+489.78%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Nicholas Stewart Green MBA
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 371
- Beta
- 1.41
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -0.58
Financials
Revenue
$33.48M+489.8%Net Income
$-17.41MEBITDA
$-10.16MFree Cash Flow
$10.38MEPS (diluted)
$-0.27Shares Outstanding (diluted)
63.84M+144.8%Operating Expenses
$10.59MCash & Debt
$33.41MReturn of Capital
$0.00Revenue by Segment (annual)
$149.27MDividend per Share
$0.66Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2023 | $139.91M | $-140.75M | $-2.23 |
| 2022 | $149.27M | $560.0K | $0.01 |
| 2021 | $119.60M | $127.67M | $2.08 |
| 2020 | $95.87M | $11.21M | $0.06 |
| 2019 | $59.70M | $-7.26M | $-0.13 |
| 2018 | $53.60M | $-4.21M | $-0.08 |
| 2017 | $53.62M | $-21.81M | $-0.46 |
| 2016 | $57.63M | $-28.16M | $-0.76 |
| 2015 | $44.69M | $-55.65M | $-1.80 |
| 2014 | $26.78M | $-50.36M | $-1.93 |
| 2013 | $22.40M | $-35.36M | $-1.53 |
| 2012 | $21.68M | $-29.78M | $-1.73 |
| 2011 | $15.23M | $-42.12M | $-3.53 |
| 2010 | $13.49M | $-34.15M | $-3.93 |
Valuation
CDMOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·14d ago·Neutral
Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for the treatment of hematologic malignancies and solid tumors, today highlighted the expanded infrastructure, technical expertise and manufacturing capabilities supporting its lead p…
View source ↗ - Newsprnewswire.com·28d ago·Neutral
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business Following the conclusion of the PinCell option and license arrangements, Scinai concentrates resources on its NanoAb platform and CDMO commercial execution, without taking on additional PC111 funding commitments JERUSALEM, Sept. 8, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.
View source ↗ - Newsprnewswire.com·57d ago·Neutral
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration Appointment strengthens operational infrastructure and supports integration and scale-up of Scinai's expanded CDMO platform. JERUSALEM, Aug. 10, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd.
View source ↗
Earnings
Typical surprise -108.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Dec 10$-0.27 vs $-0.12miss
- Mon, Sep 9$-0.09 vs $-0.04miss
- Tue, Jul 2$-1.94 vs $-0.04miss
- Wed, Apr 24$-0.08 vs $-0.02miss
- Thu, Dec 7$-0.12 vs $-0.06miss
- Thu, Sep 7$-0.03 vs $-0.03beat
Estimates and results for CDMO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CDMO officers and directors.
- Bought
- —
- Sold
- $78k
0 trades
3 trades
- Richieri Richard A.sold
- Richieri Richard A.sold
- Richieri Richard A.sold
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CDMO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.